Skip to main content

CORRECTION article

Front. Immunol., 10 February 2022
Sec. Inflammation
Volume 12 - 2021 | https://doi.org/10.3389/fimmu.2021.815903

Corrigendum: Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study

This article is a correction to:

  1. Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study

    1. Read original article
Xiao Jiang&#x;Xiao Jiang1†Chun-Mei Huang&#x;Chun-Mei Huang2†Chun-Mei FengChun-Mei Feng3Zheng XuZheng Xu3Lin Fu,*Lin Fu3,4*Xin-Ming Wang,*Xin-Ming Wang5,6*
  • 1Department of Nephrology, First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 2Anhui Province Key Laboratory of Major Autoimmune Diseases, Anhui Institute of Innovative Drugs, School of Pharmacy, Anhui Medical University, Hefei, China
  • 3Respiratory and Critical Care Medicine, Second Affiliated Hospital of Anhui Medical University, Hefei, China
  • 4Department of Toxicology, Anhui Medical University, Hefei, China
  • 5Department of Pharmacy, First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 6Third-Grade Pharmaceutical Chemistry Laboratory of State Administration of Traditional Chinese Medicine, Hefei, China

A Corrigendum on:
Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study

By Jiang X, Huang C-M, Feng C-M, Xu Z, Fu L and Wang X-M (2021). Front. Immunol. 12:714026. doi: 10.3389/fimmu.2021.714026

There is an error in the ethics name and number in the section of Study Design and Subjects. The correct ethics name and number is “Ethics Committee of Second Affiliated Hospital of Anhui Medical University (YX2021-085)”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: S100A12, community-acquired pneumonia, CAP severity score, prognosis, biomarker

Citation: Jiang X, Huang C-M, Feng C-M, Xu Z, Fu L and Wang X-M (2022) Corrigendum: Associations of Serum S100A12 With Severity and Prognosis in Patients With Community-Acquired Pneumonia: A Prospective Cohort Study. Front. Immunol. 12:815903. doi: 10.3389/fimmu.2021.815903

Received: 16 November 2021; Accepted: 17 November 2021;
Published: 10 February 2022.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2022 Jiang, Huang, Feng, Xu, Fu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Xin-Ming Wang, d2FuZ3hpbm1pbmdAYWhtdS5lZHUuY24=; Lin Fu, ZnVsaW5AYWhtdS5lZHUuY24=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.